- Trials with a EudraCT protocol (361)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
361 result(s) found for: Cytology.
Displaying page 1 of 19.
EudraCT Number: 2014-005553-39 | Sponsor Protocol Number: 1501 | Start Date*: 2015-12-29 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects of Sativex on blood leukocytes in patients with lymphoma/chronic lymphocytic leukaemia | ||
Medical condition: Lymphoma and chronic lymphocytic leukaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005017-71 | Sponsor Protocol Number: CHOCOLATE | Start Date*: 2016-04-02 | |||||||||||
Sponsor Name:Centre François Baclesse | |||||||||||||
Full Title: Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study | |||||||||||||
Medical condition: Patient with a thyroid nodule ≥15mm with indefinite cytology according to the 2008 Bethesda classification (vesicular lesion of undetermined significance; follicular neoplasm or cell Hürthle; lesi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005695-15 | Sponsor Protocol Number: NL56123.031.15 | Start Date*: 2017-07-14 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:NKI-AVL | ||||||||||||||||||||||||||||||||||||||
Full Title: Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study | ||||||||||||||||||||||||||||||||||||||
Medical condition: Gastric cancer with peritoneal carcinomatosis or tumour positive cytology | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) DK (Ongoing) FI (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000228-33 | Sponsor Protocol Number: CE/17-12-06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU Saint-Pierre | |||||||||||||
Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women | |||||||||||||
Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001791-36 | Sponsor Protocol Number: 310781 | Start Date*: 2008-01-24 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo onc... | ||
Medical condition: Vasomotor symptoms (hot flushes) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) NL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000179-41 | Sponsor Protocol Number: 26051 | Start Date*: 2008-09-11 | |||||||||||
Sponsor Name:Mundipharma Research Ltd | |||||||||||||
Full Title: Intrathecal chemotherapy with liposomal ara-C (Depocyte) in leptomeningeal metastases of solid tumors: a phase III study | |||||||||||||
Medical condition: Leptomeningeal metastasis (LM) from solid tumors, in adult patients . | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017282-35 | Sponsor Protocol Number: 113617 | Start Date*: 2010-07-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects | ||
Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) NL (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005001-20 | Sponsor Protocol Number: HIVECR | Start Date*: 2015-05-21 |
Sponsor Name:DR. ALEJANDRO SOUSA ESCANDÓN | ||
Full Title: CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH NMIBT: COMPARATIVE, PROSPECTIVE AND RANDOMIZED STUDY OF EFFICACY AND TOLERABILITY | ||
Medical condition: NMIBT | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003131-16 | Sponsor Protocol Number: 20584 | Start Date*: 2021-01-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus... | |||||||||||||
Medical condition: Treatment of pain related to endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SK (Completed) FI (Completed) NO (Completed) AT (Completed) LT (Completed) PL (Completed) BE (Completed) BG (Prematurely Ended) HU (Completed) GR (Completed) EE (Completed) LV (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000608-16 | Sponsor Protocol Number: 5466 | Start Date*: 2011-12-21 |
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust [...] | ||
Full Title: To evaluate the safety and effectiveness of human ex vivo expanded autologous limbal stem cells for the treatment of unilateral total limbal stem cell deficiency | ||
Medical condition: unilateral total limbal stem cell deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000138-37 | Sponsor Protocol Number: PERISCOPE | Start Date*: 2013-09-25 | ||||||||||||||||
Sponsor Name:NKI-AvL | ||||||||||||||||||
Full Title: Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy | ||||||||||||||||||
Medical condition: Gastric cancer with peritoneal carcinomatosis or positive peritoneal cytology. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005748-12 | Sponsor Protocol Number: 2012.761 | Start Date*: 2013-04-26 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study | |||||||||||||
Medical condition: Gastric adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000177-25 | Sponsor Protocol Number: ATA129-EBV-205 | Start Date*: 2021-01-04 | |||||||||||
Sponsor Name:Atara Biotherapeutics, Inc. | |||||||||||||
Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases | |||||||||||||
Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) AT (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008124-33 | Sponsor Protocol Number: 112024 | Start Date*: 2009-10-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn... | ||
Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000059-38 | Sponsor Protocol Number: 21810 | Start Date*: 2021-11-17 | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women. | |||||||||||||
Medical condition: Vasomotor symptoms associated with menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001888-40 | Sponsor Protocol Number: DEP NHL-P 001.A | Start Date*: 2006-07-24 | |||||||||||
Sponsor Name:Mundipharma Research Ltd. | |||||||||||||
Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg... | |||||||||||||
Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003028-59 | Sponsor Protocol Number: NL62684.091.17 | Start Date*: 2018-06-06 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study | ||
Medical condition: Anaplastic Thyroid Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004269-14 | Sponsor Protocol Number: HP002-001 | Start Date*: 2018-05-07 |
Sponsor Name:Hamlet Pharma AB | ||
Full Title: A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery | ||
Medical condition: Non-muscle invasive bladder cancer awaiting transurethral surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003466-34 | Sponsor Protocol Number: M06OVH | Start Date*: 2006-12-14 |
Sponsor Name:NKI-AVL | ||
Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I) | ||
Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001005-82 | Sponsor Protocol Number: TALL/IP/2 | Start Date*: 2015-05-05 |
Sponsor Name:Galileo Research Srl | ||
Full Title: Phase II trial of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with ovarian carcinoma with minimal or microscopic residual disease at second look laparotom... | ||
Medical condition: Ovarian carcinoma (FIGO stage IIIA and IIIB/IIIC/IV; patients with extra-abdominal disease will be excluded by the study unless those with pleural effusion) with minimal/microscopic residual disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.